$16.31
2.95% yesterday
Nasdaq, Nov 18, 10:00 pm CET
ISIN
US8902604094
Symbol
TNXP

Tonix Pharmaceuticals Holding Corp. Stock price

$16.31
-3.53 17.79% 1M
-10.29 38.68% 6M
-16.67 50.55% YTD
+3.01 22.63% 1Y
-8,425.69 99.81% 3Y
-369,519.69 100.00% 5Y
-4,211,199,983.69 100.00% 10Y
-1,279,983.69 100.00% 20Y
Nasdaq, Closing price Tue, Nov 18 2025
-0.50 2.95%
ISIN
US8902604094
Symbol
TNXP
Industry

Key metrics

Basic
Market capitalization
$197.9m
Enterprise Value
$72.6m
Net debt
positive
Cash
$125.3m
Shares outstanding
7.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.1 | 17.1
EV/Sales
7.4 | 6.3
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
85.7%
Return on Equity
-93.2%
ROCE
-50.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.8m | $11.6m
EBITDA
$-82.5m | -
EBIT
$-84.5m | $-108.2m
Net Income
$-81.4m | $-101.1m
Free Cash Flow
$-65.4m
Growth (TTM | estimate)
Revenue
-21.1% | 14.8%
EBITDA
8.6% | -
EBIT
11.3% | -39.2%
Net Income
45.4% | 22.3%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
29.3%
EBITDA
-839.1% | -
EBIT
-859.3%
Net
-828.2% | -872.7%
Free Cash Flow
-665.1%
More
EPS
$-11.1
FCF per Share
$-8.7
Short interest
16.0%
Employees
81
Rev per Employee
$120.0k
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
88%
Hold
13%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9.83 9.83
21% 21%
100%
- Direct Costs 6.95 6.95
29% 29%
71%
2.88 2.88
7% 7%
29%
- Selling and Administrative Expenses 50 50
34% 34%
505%
- Research and Development Expense 36 36
41% 41%
363%
-82 -82
9% 9%
-839%
- Depreciation and Amortization 1.98 1.98
60% 60%
20%
EBIT (Operating Income) EBIT -84 -84
11% 11%
-859%
Net Profit -81 -81
45% 45%
-828%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
one day ago
TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated CHATHAM, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasd...
Positive
Seeking Alpha
4 days ago
Tonix Pharmaceuticals is preparing for the commercial launch of Tonmya, a new FDA-approved fibromyalgia therapy, in November 2025. 3Q25 results showed revenue growth and a strong cash position, but higher SG&A expenses reflect heavy investment in commercialization efforts. Key risks for TNXP include patient adoption challenges and uncertainties around insurance coverage and payer reimbursement ...
Neutral
GlobeNewsWire
8 days ago
Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE)...
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today